Back to Journals » Journal of Experimental Pharmacology » Volume 12

Antiviral Effects of Oleandrin

Authors Newman RA, Sastry KJ, Arav-Boger R, Cai H, Matos R, Harrod R

Received 4 September 2020

Accepted for publication 25 October 2020

Published 16 November 2020 Volume 2020:12 Pages 503—515

DOI https://doi.org/10.2147/JEP.S273120

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Arthur Frankel


Robert A Newman, 1, 2 K Jagannadha Sastry, 3 Ravit Arav-Boger, 4 Hongyi Cai, 5 Rick Matos, 6 Robert Harrod 7

1Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA; 2Phoenix Biotechnology, Inc, San Antonio, TX 78217, USA; 3Departments of Thoracic, Head and Neck Medical Oncology and Veterinary Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 4Division of Infectious Diseases, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA; 5National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA; 6Innovar, LLC, Plano, TX 75025, USA; 7Department of Biological Sciences, the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX 75275, USA

Correspondence: Robert A Newman Tel +1-7138578921
Email newmanscientificconsulting@gmail.com

Abstract: Over the past 15 years, investigators have reported on the utility and safety of cardiac glycosides for numerous health benefits including those as treatments for malignant disease, stroke-mediated ischemic injury and certain neurodegenerative diseases. In addition to those, there is a growing body of evidence for novel antiviral effects of selected cardiac glycoside molecules. One unique cardiac glycoside, oleandrin derived from Nerium oleander, has been reported to have antiviral activity specifically against ‘enveloped’ viruses including HIV and HTLV-1. Importantly, a recent publication has presented in vitro evidence for oleandrin’s ability to inhibit production of infectious virus particles when used for treatment prior to, as well as after infection by SARS-CoV-2/COVID-19. This review will highlight the known in vitro antiviral effects of oleandrin as well as present previously unpublished effects of this novel cardiac glycoside against Ebola virus, Cytomegalovirus, and Herpes simplex viruses.

Keywords: oleandrin, Nerium oleander, virus, Na, K-ATPase, antiviral therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]